Genelux (GNLX) Operating Expenses (2022 - 2026)
Genelux's (GNLX) quarterly Operating Expenses came in at $9.2 million in Q1 2026, up 17.34% year-on-year from $7.8 million in Q1 2025, and down 2.64% quarter-over-quarter from $9.4 million in Q4 2025.
Genelux (GNLX) Operating Expenses (2022 - 2026) Analysis & Trends
Genelux's Operating Expenses history runs 5 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- On a quarterly basis, Operating Expenses rose 17.34% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 10.13% increase from a year earlier, with the FY2025 full-year figure at $33.2 million, up 4.79% from the prior year.
- Operating Expenses eased to $9.2 million in Q1 2026 per GNLX's latest filing, from $9.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $9.7 million in Q4 2024 and bottomed at $3.2 million in Q4 2022.
- The 5-year median for Operating Expenses is $7.0 million (2023), against an average of $7.1 million.
- Across the five-year window, Operating Expenses surged 121.41% in 2023 and slipped 3.78% in 2025, its largest moves.
- Year by year, Operating Expenses stood at $3.2 million in 2022, then surged by 121.41% to $7.0 million in 2023, then surged by 39.24% to $9.7 million in 2024, then dropped by 3.36% to $9.4 million in 2025, then decreased by 2.64% to $9.2 million in 2026.
- Per Business Quant, the three latest GNLX Operating Expenses figures stand at $9.2 million (Q1 2026), $9.4 million (Q4 2025), and $8.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | 15.76 Mn |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn | 1.10 Bn |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 9.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.17 Mn |
| Dec 31, 2025 | 9.42 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Mar 31, 2025 | 7.82 Mn |
| Dec 31, 2024 | 9.75 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.12 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 5.40 Mn |
| Mar 31, 2023 | 6.63 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 4.66 Mn |